LYNGBY, DENMARK – Novozymes and Chr. Hansen completed their merger, creating a company called Novonesis with 10,000 employees, a global research and development network and application centers and activities in 30 industries. Annual revenue will be around €3.7 billion ($4 billion USD).
Half of Novonesis’ portfolio will focus on enabling healthier lives and producing better foods, according to the company, while the other half will work to reduce chemical use and target climate-neutral practices. Novozymes provided enzymes and microbial technology. Chr. Hansen develops ingredient systems for the food, pet food, nutritional, pharmaceutical and agricultural industries.
Novozymes and Chr. Hansen entered into an agreement to merge on December 12, 2022. The name combines the word “novo,” meaning new from the Latin word de novo (new), and “Genesis,” the Greek word for origin or beginning.
“We successfully integrated Novozymes and Chr. Hansen, and today we come together as a leading global bio-solutions partner,” said Ester Baiget, president and chief executive officer of Novonesis. “Novenesis brings together our joint strengths and the wonders of biology, and we are set to lead a new era of bio-solutions.”
Cees de Jong, chairman of Novonesis added, “We will continue to create powerful bio-solutions for our customers and partners based on our more than 100 years of innovation and application expertise. Together, we will serve as a growth partner to our customers, a value creator to our shareholders, and a company with a meaningful, positive impact on society and the planet.”
Read more about corporate strategy, financial performance, mergers and acquisitions on our Business page.
